News

Glide Technologies Announces Successful £3.2 Million ($4.0 Million) Fundraising

February 1, 2017: Glide Technologies Announces Successful £3.2 Million ($4.0 Million) Fundraising

Glide Technologies, the pharmaceutical development and device company focused on the needle-free administration of solid… read more

Glide Technologies announces successful clinical proof-of-concept study

June 28, 2016: Glide Technologies announces successful clinical proof-of-concept study

OXFORD, UK – 28 June 2016 – Glide Technologies today announced results from a successful… read more

Glide Technologies Initiates Clinical Proof-of-Concept Study with Novel Octreotide Solid Dose Formulation Delivered via Needle-Free SDI®

May 19, 2016: Glide Technologies Initiates Clinical Proof-of-Concept Study with Novel Octreotide Solid Dose Formulation Delivered via Needle-Free SDI®

OXFORD, UK – 19 May 2016 – Glide Technologies, the pharmaceutical development and device company… read more

Glide Technologies presenting at BioTrinity – 26th – 27th April 2016

April 19, 2016: Glide Technologies presenting at BioTrinity – 26th – 27th April 2016

Glide Technologies’ CEO, Mark Carnegie-Brown, will be presenting at BioTrinity 2016 on 27th April 2016… read more

Glide Technologies is attending Bio-Europe Spring Conference 4th – 6th April 2016

April 1, 2016: Glide Technologies is attending Bio-Europe Spring Conference 4th – 6th April 2016

Glide Technologies’ Chief Business Officer, Tony Mills will be attending the Bio-Europe Spring conference in Stockholm.

Glide Technologies’ CEO, Mark Carnegie-Brown, will be in San Francisco 11th – 14th January 2016 during the JP Morgan conference

January 8, 2016: Glide Technologies’ CEO, Mark Carnegie-Brown, will be in San Francisco 11th – 14th January 2016 during the JP Morgan conference

Glide Technologies’ CEO, Mark Carnegie-Brown, will be in San Francisco 11th – 14th January 2016… read more

Glide Technologies Announces Successful Proof-of-Concept with Novel Exenatide Solid Dose Formulation

January 6, 2016: Glide Technologies Announces Successful Proof-of-Concept with Novel Exenatide Solid Dose Formulation

OXFORD, UK – 6 January 2016 – Glide Technologies, the development company focused on solid… read more

Glide Technologies is attending the 21st annual Bio-Europe conference 2nd – 4th November 2015

October 30, 2015: Glide Technologies is attending the 21st annual Bio-Europe conference 2nd – 4th November 2015

Glide Technologies’ Director of Business Development, Tony Mills will be attending the 21st annual Bio-Europe… read more

Glide Technologies presents at 5th Annual PODD, Partnership Opportunities in Drug Delivery

October 1, 2015: Glide Technologies presents at 5th Annual PODD, Partnership Opportunities in Drug Delivery

Mark Carnegie-Brown, CEO, will be presenting the benefits of Glide Technologies’ solid dose injector (‘SDI®’) at… read more

Glide Technologies Announces Collaboration with Cilian AG to Develop Novel Solid Dose Recombinant Influenza Vaccine

September 21, 2015: Glide Technologies Announces Collaboration with Cilian AG to Develop Novel Solid Dose Recombinant Influenza Vaccine

Glide Technologies, the development company focused on solid dose formulations of therapeutics and vaccines, today… read more

Glide Technologies presents at the 6th APS International PharmSci Conference

September 8, 2015: Glide Technologies presents at the 6th APS International PharmSci Conference

Chris Macgregor, Glide Technologies’ Head of Manufacturing, will be presenting a paper entitled ‘Solid dose delivery… read more

23 April 2015: Glide Technologies Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Teriparatide SDI®

April 23, 2015: 23 April 2015: Glide Technologies Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Teriparatide SDI®

Glide Technologies, the development company focused on solid dose formulations of therapeutics and vaccines and… read more

Glide Announces Successful Results from Skin Delivery and Human Factor Studies with Novel Solid Dose Injection System

March 16, 2015: Glide Announces Successful Results from Skin Delivery and Human Factor Studies with Novel Solid Dose Injection System

Glide Technologies, the development company focused on solid dose formulations of therapeutics and vaccines and… read more

Pfenex exercises Glide contract extension for solid dose formulation of recombinant protective antigen

March 9, 2015: Pfenex exercises Glide contract extension for solid dose formulation of recombinant protective antigen

Glide Technologies announced today a subcontract extension for the advancement of an alternative delivery method… read more

Glide Appoints Albany Molecular Research for Manufacture of Novel Octreotide Solid Dose Formulation Clinical Trial Product

January 26, 2015: Glide Appoints Albany Molecular Research for Manufacture of Novel Octreotide Solid Dose Formulation Clinical Trial Product

Glide Technologies, the development company focused on solid dose formulations of therapeutics and vaccines and… read more

Glide Pharma Takes Exclusive Worldwide Rights to Novel Diagnostic Technology for Prostate Cancer

July 29, 2014: Glide Pharma Takes Exclusive Worldwide Rights to Novel Diagnostic Technology for Prostate Cancer

Glide Pharma, the pharmaceutical development and device company focused on solid dose formulations of therapeutics… read more

Glide Pharma Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Octreotide

July 22, 2014: Glide Pharma Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Octreotide

Glide Pharma, the pharmaceutical development and device company focused on solid dose formulations of therapeutics… read more

Glide Pharma Appoints Richard Bungay as Chief Financial Officer and Tony Mills as Director of Business Development

July 8, 2014: Glide Pharma Appoints Richard Bungay as Chief Financial Officer and Tony Mills as Director of Business Development

Glide Pharma, the pharmaceutical development and device company focused on solid dose formulations of therapeutics… read more

Glide Pharma win Oxford Biotech Network award for “best medtech fundraiser” at the OBN awards ceremony.

October 9, 2013: Glide Pharma win Oxford Biotech Network award for “best medtech fundraiser” at the OBN awards ceremony.

Glide Pharma was awarded Best Medtech Fundraiser at the OBN’s Annual Awards Dinner on 02… read more

Glide Pharma Appoints Bryan G Morton as Chairman and Announces Board Changes

October 9, 2013: Glide Pharma Appoints Bryan G Morton as Chairman and Announces Board Changes

Glide Pharma, the pharmaceutical development and device company focused on the needle-free administration of solid… read more

Glide Pharma Announces Design Optimisation Agreement With Nypro Healthcare For Scale Up Of Solid Dose Delivery Device

July 2, 2013: Glide Pharma Announces Design Optimisation Agreement With Nypro Healthcare For Scale Up Of Solid Dose Delivery Device

Glide Pharma today announced that it has entered an agreement with global device manufacturer Nypro… read more

Pfenex Inc. Awards Glide Pharma Development Contract for a Solid Formulation of Recombinant Anthrax Vaccine

April 30, 2013: Pfenex Inc. Awards Glide Pharma Development Contract for a Solid Formulation of Recombinant Anthrax Vaccine

Glide Pharma today announced the award of a sub-contract from Pfenex Inc. to develop a… read more

Glide Pharma Appoints Dr Mark Carnegie-Brown as Chief Executive

March 6, 2013: Glide Pharma Appoints Dr Mark Carnegie-Brown as Chief Executive

Glide Pharma, the pharmaceutical development and device company focused on the needle-free administration of solid… read more

Glide Pharma Completes £14.0 Million Fundraising For Drug and Device Manufacturing and Product Development

February 26, 2013: Glide Pharma Completes £14.0 Million Fundraising For Drug and Device Manufacturing and Product Development

Glide Pharma, the pharmaceutical development and device company focused on the needle-free administration of solid… read more

Glide Pharma Announces £2.3 Million ($3.7 Million) Award from UK Biomedical Catalyst for Development of Osteoporosis Treatment

November 5, 2012: Glide Pharma Announces £2.3 Million ($3.7 Million) Award from UK Biomedical Catalyst for Development of Osteoporosis Treatment

Glide Pharma, the specialty pharmaceutical company focused on the easy, safe and convenient administration of… read more